Business
First Three Children to Commence Treatment With Ryoncil®
United States Centers for Medicare and Medicaid Services (CMS) Mandates Ryoncil® CoverageNEW YORK, March 30, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has entered into the Medicaid National Drug Rebate Agreement (NDRA) with the U.S. Centers for Medicare & Medicaid Services (CMS), Department of Health and Human Services, for Ryoncil® (remestemcel-L), the first mesenchymal stromal cel
About this update from Mesoblast Limited
[{"type":"image","alt":"Mesoblast Limited","displaySize":"","headline":null,"caption":"Mesoblast Limited","className":"","disableSlideshowImg":false,"size":{"original":{"width":289,"height":38,"url":"https://media.zenfs.com/en/globenewswire.com/3a26a2f63129fae6650ef7618b48c2df"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/qVvwFFYM1KHQf5WBcCEDQw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTU1O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/3a26a2f63129fae6650ef7618b48c2df","width":289,"height":38}},"lazy":false},{"type":"text","content":"United States Centers for Medicare and Medicaid Services (CMS) Mandates Ryoncil® Coverage","length":89,"tagName":"p"},{"type":"text","content":"NEW YORK, March 30, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has entered into the Medicaid National Drug Rebate Agreement (NDRA) with the U.S. Centers for Medicare & Medicaid Services (CMS), Department of Health and Human Services, for Ryoncil® (remestemcel-L), the first mesenchymal stromal cell (MSC) therapy approved by U.S. Food and Drug Administration (FDA) for any indication. The NDRA agreement with Mesoblast means that the U.S. Government now provides inpatient and outpatient access for a treatment course of Ryoncil® to the approximately 40% of U.S. children covered by Medicaid who have steroid-refractory acute graft versus host disease (SR-aGvHD), the remainder being covered by private insurance. U.S. states have the option to immediately cover Ryoncil®, with mandatory coverage commencing July 1, 2025.","length":939,"tagName":"p"},{"type":"text","content":"The first three children with SR-aGvHD will receive a course of Ryoncil® commencing this week. Ryoncil® is an allogeneic MSC therapy for treatment of pediatric patients 2 months and older, including adolescents and teenagers, with SR-aGvHD, a condition with high mortality rates. The recommended course of Ryoncil® for pediatric SR-aGvHD is 2×106 MSC/kg body weight per intravenous infusion given twice per week for 4 consecutive weeks. Additional information is available on ryoncil.com, where valuable resources for healthcare providers, patients and caregivers can be found.","length":577,"tagName":"p"},{"type":"text","content":"Mesoblast Chief Executive Dr. Silviu Itescu said: “We are delighted to be ...